May A Beydoun1, Sharmin Hossain2, Kumaraswamy Naidu Chitrala2, Salman M Tajuddin2, Hind A Beydoun3, Michele K Evans2, Alan B Zonderman2. 1. Laboratory of Epidemiology and Population Sciences, National Institute on Aging, NIA/NIH/IRP, Baltimore, MD, United States. Electronic address: baydounm@mail.nih.gov. 2. Laboratory of Epidemiology and Population Sciences, National Institute on Aging, NIA/NIH/IRP, Baltimore, MD, United States. 3. Department of Research Programs, Fort Belvoir Community Hospital, Fort Belvoir, VA, United States.
Abstract
OBJECTIVE: This study tests associations of DNA methylation-based (DNAm) measures of epigenetic age acceleration (EAA) with cross-sectional and longitudinal depressive symptoms in an urban sample of middle-aged adults. METHODS: White and African-American adult participants in the Healthy Aging in Neighborhoods of Diversity across the Life Span study for whom DNA samples were analyzed (baseline age: 30-65 years) we included. We estimated three DNAm based EAA measures: (1) universal epigenetic age acceleration (AgeAccel); (2) intrinsic epigenetic age acceleration (IEAA); and (3) extrinsic epigenetic age acceleration (EEAA). Depressive symptoms were assessed using the 20-item Center for Epidemiological Studies-Depression scale total and sub-domain scores at baseline (2004-2009) and follow-up visits (2009-2013). Linear mixed-effects regression models were conducted, adjusting potentially confounding covariates, selection bias and multiple testing (N = 329 participants, ∼52% men, k = 1.9 observations/participant, mean follow-up time∼4.7 years). RESULTS: None of the epigenetic age acceleration measures were associated with total depressive symptom scores at baseline or over time. IEAA - a measure of cellular epigenetic age acceleration irrespective of white blood cell composition - was cross-sectionally associated with decrement in "positive affect" in the total population (γ011± SE = -0.090 ± 0.030, P = 0.003, Cohen's D: -0.16) and among Whites (γ011 ± SE = -0.135 ± 0.048, P = 0.005, Cohen's D: -0.23), after correction for multiple testing. Baseline "positive affect" was similarly associated with AgeAccel. LIMITATIONS: Limitations included small sample size, weak-moderate effects and measurement error. CONCLUSIONS: IEAA and AgeAccel, two measures of EAA using Horvath algorithm, were linked to a reduced "positive affect", overall and among Whites. Future studies are needed to replicate our findings and test bi-directional relationships.
OBJECTIVE: This study tests associations of DNA methylation-based (DNAm) measures of epigenetic age acceleration (EAA) with cross-sectional and longitudinal depressive symptoms in an urban sample of middle-aged adults. METHODS: White and African-American adult participants in the Healthy Aging in Neighborhoods of Diversity across the Life Span study for whom DNA samples were analyzed (baseline age: 30-65 years) we included. We estimated three DNAm based EAA measures: (1) universal epigenetic age acceleration (AgeAccel); (2) intrinsic epigenetic age acceleration (IEAA); and (3) extrinsic epigenetic age acceleration (EEAA). Depressive symptoms were assessed using the 20-item Center for Epidemiological Studies-Depression scale total and sub-domain scores at baseline (2004-2009) and follow-up visits (2009-2013). Linear mixed-effects regression models were conducted, adjusting potentially confounding covariates, selection bias and multiple testing (N = 329 participants, ∼52% men, k = 1.9 observations/participant, mean follow-up time∼4.7 years). RESULTS: None of the epigenetic age acceleration measures were associated with total depressive symptom scores at baseline or over time. IEAA - a measure of cellular epigenetic age acceleration irrespective of white blood cell composition - was cross-sectionally associated with decrement in "positive affect" in the total population (γ011± SE = -0.090 ± 0.030, P = 0.003, Cohen's D: -0.16) and among Whites (γ011 ± SE = -0.135 ± 0.048, P = 0.005, Cohen's D: -0.23), after correction for multiple testing. Baseline "positive affect" was similarly associated with AgeAccel. LIMITATIONS: Limitations included small sample size, weak-moderate effects and measurement error. CONCLUSIONS: IEAA and AgeAccel, two measures of EAA using Horvath algorithm, were linked to a reduced "positive affect", overall and among Whites. Future studies are needed to replicate our findings and test bi-directional relationships.
Authors: Christoph Anacker; Patricia A Zunszain; Livia A Carvalho; Carmine M Pariante Journal: Psychoneuroendocrinology Date: 2011-04 Impact factor: 4.905
Authors: Michele K Evans; James M Lepkowski; Neil R Powe; Thomas LaVeist; Marie Fanelli Kuczmarski; Alan B Zonderman Journal: Ethn Dis Date: 2010 Impact factor: 1.847
Authors: D Gimeno; M Kivimäki; E J Brunner; M Elovainio; R De Vogli; A Steptoe; M Kumari; G D O Lowe; A Rumley; M G Marmot; J E Ferrie Journal: Psychol Med Date: 2008-06-04 Impact factor: 7.723
Authors: May A Beydoun; Nicole Noren Hooten; Michele K Evans; Alan B Zonderman; Jordan Weiss; Hind A Beydoun; Sharmin Hossain Journal: BMC Med Date: 2022-06-13 Impact factor: 11.150
Authors: Nicole Beaulieu Perez; Allison A Vorderstrasse; Gary Yu; Gail D'Eramo Melkus; Fay Wright; Stephen D Ginsberg; Cindy A Crusto; Yan V Sun; Jacquelyn Y Taylor Journal: Epigenet Insights Date: 2022-06-28
Authors: May A Beydoun; Hind A Beydoun; Nicole Noren Hooten; Ana I Maldonado; Jordan Weiss; Michele K Evans; Alan B Zonderman Journal: Aging (Albany NY) Date: 2022-07-01 Impact factor: 5.955